Massachusetts General Hospital Selects Elekta as New Vendor for Complete Cancer Treatment Solution

Regulatory News:

Massachusetts General Hospital (MGH) Cancer Center has purchased four radiation therapy treatment systems from Elekta (STO:EKTAB), including three Elekta Infinity and one Elekta Synergy® S. The order, which includes information management software, will enable the facility to offer patients a complete cancer treatment solution from the company.

The three Infinity systems position MGH to take advantage of Volumetric Modulated Arc Therapy (VMAT), a new radiation therapy technique that allows clinicians to deliver tightly focused radiation treatments in less time. A treatment session typically can be conducted in five minutes or less and delivered with single or multiple arcs depending upon the patients needs.

Elekta Infinity also supports all forms of Intensity Modulated Radiation Therapy (IMRT) and Image Guided Radiation Therapy (IGRT).

MGH also purchased Elekta Synergy S, a state-of-the-art digital linear accelerator with integrated imaging capabilities. The facility will use Elekta Synergy S to perform Stereotactic Radiosurgery (SRS) and Stereotactic Radiotherapy (SRT) throughout the body, as well as hypofractionated treatments utilizing IGRT and VMAT.

The four treatment machines also feature the HexaPOD™ evo RT system, a vision guided patient positioning platform with six degrees of freedom. Six degrees of freedom means that the system can detect and correct misalignments in patient positioning —making it ideal for the very high accuracy required during critical radiation treatments.

About Elekta

Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated state of the art tools and treatment planning systems for radiation therapy and radiosurgery, as well as workflow enhancing software systems across the spectrum of cancer care.

Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives, making the future possible today.

Today, Elekta solutions in oncology and neurosurgery are used in over 5,000 hospitals globally, and every day more than 100,000 patients receive diagnosis, treatment or follow-up with the help of a solution from the Elekta Group.

Elekta employs around 2,500 employees globally. The corporate headquarter is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb. For more information about Elekta, please visit www.elekta.com.

This information was brought to you by Cision http://www.cisionwire.com